Biomarkers in Diabetic Kidney Disease: Early Detection, Prognostic Assessment, and Integration with Multi-Omics...

Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease and end-stage kidney disease worldwide, imposing a major clinical and economic burden. Conventional diagnostic markers, including albuminuria and estimated glomerular filtration rate (eGFR), have limited sensitivity and specificity for early disease detection and for accurately predicting progression. Increasing evidence suggests that DKD involves complex glomerular, tubular, inflammatory, fibrotic, and oxidative stress pathways that precede overt clinical manifestations. Consequently, considerable attention has focused on identifying novel noninvasive biomarkers, particularly urinary biomarkers, alongside selected circulating biomarkers and emerging multi-omics signatures. Proteins, peptides, extracellular vesicles, and RNA-based biomarkers have demonstrated promising diagnostic and prognostic potential for detecting early renal injury, improving risk stratification, and monitoring therapeutic response. This review summarizes recent advances in biomarker research for DKD, highlighting emerging molecular and omics-based signatures that may complement conventional markers in improving early detection, prognostic assessment, and disease phenotyping. While numerous biomarkers have shown promising associations with renal outcomes and disease progression, the majority remain investigational. Their translation into routine clinical practice will depend on rigorous external validation, standardized analytical methods, and demonstration of added value beyond established clinical measures.